Brainstorm Health: Xarelto TV Ads, Paid for Staying in Bed, Bristol Myers Celgene Deal

Happy Friday, readers! I’m running around prepping for our upcoming Brainstorm Health conference (hey, I’ve mentioned that’s happening next week and is going to be awesome, right?) so it’ll have to be a short one this beautiful Friday afternoon. But here’s something worth noting–Johnson & Johnson is reportedly getting ahead of the regulatory curve to become the first drug company in the U.S. to spell out a treatment’s price in direct-to-consumer television ads, for the blood thinner . The Trump administration has been preparing rules along these lines to mandate the disclosures in pharma ads. J&J is also addressing one of the main criticisms of the proposed rules–that list prices are often substantially different from what patients actually pay for …

Brainstorm Health: Health Care AI, Quarterly Biotech Reports, Novartis Deal

Happy Monday, readers. I’m on my way to the Fortune Brainstorm Health conference in San Diego, where our ridiculously stacked speaker set will address, well, a good chunk of things worth addressing in the digital health, biopharma, and public health spheres. A study published in the journal Nature Digital Medicine last week just happens to happily coincide with our Southern California get together. It raises one the most important questions in this nascent era of algorithmic medicine–when are AI and big data analytics most effective in real world medicine? The authors propose some theories following an extensive, and unique, collaboration between AI researchers and medical professionals at Stanford and Utah’s Intermountain LDS Hospital system, the MIT Technology Review reports. In …